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OBJECTIVE — Flicker-induced vasodilatation is reduced in patients with vascular-related
diseases, which has at least partially been attributed to endothelial dysfunction of retinal vessels.
Currently, the standard method to assess endothelial function in vivo is ﬂow-mediated vasodi-
latation(FMD).Thus,thepresentstudywasperformedtoinvestigatewhetheracorrelationexists
between ﬂicker-induced vasodilatation and FMD in patients with known endothelial dysfunc-
tion and healthy subjects.
RESEARCH DESIGN AND METHODS — In the present study, 20 patients with type 1
diabetes, 40 patients with systemic hypertension (systolic blood pressure 140–159 mmHg;
diastolic blood pressure 90–99 mmHg) and/or serum cholesterol levels 0.65 mmol/l, and 20
healthy control subjects were included. The ﬂicker response was measured using the Dynamic
Retinal Vessel Analyzer. FMD was determined using a high-resolution ultrasound system, mea-
suring brachial artery diameter reactivity during reperfusion after arterial occlusion.
RESULTS — The ﬂicker response of both retinal arteries and veins was signiﬁcantly reduced
in the two patients groups. Likewise, FMD was signiﬁcantly reduced in patients compared with
healthy control subjects. However, only a weak correlation between ﬂicker-induced vasodilata-
tion and FMD was observed.
CONCLUSIONS — The study conﬁrms that ﬂicker responses and FMD are reduced in the
selected patient groups. Whether the weak correlation between FMD and ﬂicker is due to the
different stimulation type, the different vascular beds measured, or other mechanisms has yet to
be investigated.
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S
timulatingtheeyewithdiffuseﬂick-
ering light is accompanied by an in-
crease in retinal vessel diameters
(1,2), retinal blood ﬂow (3), and optic
nerve head blood ﬂow (4). Although this
phenomenon has not yet been clariﬁed in
all details, there is general agreement that
the increase of blood ﬂow is caused by
augmented neural activity in ganglion
cells and the connected tissues. This,
again, underlines the tight coupling be-
tweenbloodﬂow,neuronalfunction,and
metabolism in the eye.
There is evidence that this adaptive
regulation process is impaired under sev-
eral pathological conditions. In particu-
lar, a couple of studies have shown that
patients with diabetes (5,6), arterial hy-
pertension (7), or glaucoma (8) show a
reduced blood ﬂow response to ﬂicker-
light stimulation. Given that all these dis-
eases go hand in hand with endothelial
dysfunction, it has been hypothesized
that the reduced ﬂicker response may be
related to impaired endothelial vasodila-
tation of retinal vessels. This is supported
by data showing that inhibition of nitric
oxide(NO)synthasesigniﬁcantlyreduces
ﬂicker-induced vasodilatation (9).
Whether this impaired vascular function
is just a local phenomenon or correlates
with impaired endothelial function in
other vascular beds, however, remains
unclear.
Currently, measurement of ﬂow-
mediated vasodilatation (FMD) in the
forearm is the most widely used tech-
nique for the assessment of endothelial
function in vivo. First described in 1992,
this method is based on reactive hyper-
emia after discontinuation of blood ﬂow
by inﬂating a cuff to suprasystolic values
(10). The vasodilatation of the brachial
artery is caused by shear stress-induced
NO production after cuff deﬂation. It is
knowntobeendotheliumdependentand
gives a reliable measure of endothelial
function of peripheral arteries (10).
The current study tested the hypoth-
esis that reduced ﬂicker-induced retinal
vasodilatation correlates with endothelial
dysfunction in the brachial artery, as
tested by means of FMD. FMD and
ﬂicker-induced vasodilatation were mea-
sured in healthy volunteers and in dif-
ferent groups of patients with known
endothelial dysfunction, namely pa-
tients with type 1 diabetes and patients




approved by the ethics committee of the
Medical University of Vienna and fol-
lowed the guidelines set forth in the Dec-
laration of Helsinki. All patients signed
written informed consent prior to inclu-
sion and passed a screening examination
including physical and ophthalmological
examination during the 10 days before
the study day. A total of 80 individuals
aged 18 years were included in this
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group study.
Three groups were composed: group
1 included 20 patients with type 1 diabe-
tes with no signs of diabetic retinopathy
or mild nonproliferative diabetic retinop-
athy. The eyes were classiﬁed according
totheModiﬁedArlieHouseClassiﬁcation
(11).Afurtherinclusioncriterionfortype
1 diabetic patients was a serum choles-
terol level 0.65 mmol/l.
Group 2 included 40 patients with
mild essential systemic hypertension at
rest and/or with serum cholesterol levels
0.65mmol/l.Hypertensionwasdeﬁned
as a blood pressure meeting the criterion
of hypertension grade 1 of the World
Health Organization blood pressure clas-
siﬁcation, with systolic blood pressure
(SBP) from 140 to 159 mmHg and
diastolic blood pressure (DBP) from 90 to
99 mmHg. Blood pressure was measured
at two different occasions in a sitting
position.
As a control, 20 healthy subjects with
SBP 140 mmHg, DBP 90 mmHg, se-
rumcholesterollevels0.55mmol/l,and
normal ocular ﬁndings were included in
group 3. Care was taken that the control
group was comparable in age and sex dis-
tribution to the patient groups. Further
exclusion criteria for all subjects were
ametropia 3 dpt, other relevant ocular
abnormalities, a clinically relevant illness
priortothestudy,pregnancyorlactation,
andapatientorfamilyhistoryofepilepsy.
Participants had to abstain from bever-
ages containing alcohol or caffeine for
12 h before the study.
Retinal vessel analyzer
The diameters of one temporal retinal
artery and vein between 1 and 2 disc
diameters from the margin of the optic
disc were continuously measured using
the Dynamic Vessel Analyzer (DVA;
IMEDOS, Jena, Germany). The DVA
comprises a fundus camera (FF 450; Carl
Zeiss Meditec, Jena, Germany), a digital
video camera, and a personal computer
with analyzing software for the determi-
nation of retinal vessel diameters that are
analyzed from digitized images. The sys-
tem provides excellent reproducibility
and sensitivity (12). After selection of the
measurement location, the DVA is able to
follow the vessels during movements
within the measurement window. Retinal
vessel diameters were measured for 4
min. For the second minute, full-ﬁeld
ﬂickering light with a frequency of 12.5
Hz was used for stimulation by square–
wave pattern modulation of the fundus
camera illumination at a contrast ratio of
25:1.
FMD
To measure FMD, each subject was in the
supine position with the left arm sup-
ported on a foam block and a pneumatic
cuff placed on the upper arm proximal to
the measurement area. A high-resolution
ultrasound system with a 7.0-MHz trans-
ducer (Vivid seven Pro; GE Vingmed Ul-
trasound, Horten, Norway) was used to
measurethebrachialarterydiameter.The
probe was ﬁxed in an adjustable swivel
armtomaintainanidenticalpositiondur-
ing the experiments. The brachial artery
was scanned in a longitudinal section
proximal to its bifurcation, which was
used as an anatomical marker. The end-
diastolicdiameterwasmeasured.Allmea-
surements were performed by the same
experienced operator. Baseline diameter
of the brachial artery was assessed as the
mean of 1 min of continuous measure-
ment. Thereafter, the cuff on the upper
armwasinﬂatedtosuprasystolicpressure
(250 mmHg) for 4.5 min. FMD was then
induced by sudden cuff deﬂation. The
vessel diameter was measured for the fol-
lowing 2 min.
Experimental paradigm
All subjects were studied under dilated
pupil after instillation with tropicamide
(Mydriaticum “Agepha”-Gtt; Agepha, Vi-
enna, Austria). After a 20-min resting pe-
riod in a sitting position, baseline
measurements of arterial blood pressure
and pulse rate were performed. Thereaf-
ter, retinal vessel measurements includ-
ing ﬂicker stimulation were performed.
Intraocular pressure (IOP) was measured
after the ﬂicker experiment. Finally, FMD
was assessed as described above.
Measurement of IOP and systemic
hemodynamics
IOP was measured with a slit-lamp–
mounted Goldmann applanation tonom-
eter (Haag-Streit, Bern, Switzerland).
Before each measurement, two drops of
oxybuprocainhydrochloride combined
withsodiumﬂuoresceinwereinstilledfor
local anesthesia. SBP, DBP, and mean ar-
terial blood pressures (MAP) were mea-
sured on the upper arm by an automated
oscillometric device (HP-CMS patient
monitor;HewlettPackard,PaloAlto,CA).




Changes in retinal vessel diameters were
expressedaspercentchangeoverbaseline
values. Baseline values were calculated as
an average of the last 20 s before start of
the ﬂicker stimulation. Flicker response
was calculated as an average of the last
20 s of the stimulation period. Flow-
mediated dilatation of the brachial artery
wasexpressedaspercentagechangeofdi-
ameter measured 60 s after cuff deﬂation
compared with baseline. An ANOVA
model was used for signiﬁcance testing of
the retinal vessel response to ﬂicker stim-
ulation and to FMD over time within the
groups as well as between the three
groups. Pearson product-moment corre-
lation coefﬁcient was calculated to assess
correlation between the variables. To ad-
just for multiple testing, a modiﬁed Bon-
ferroni procedure was applied (13). For
all calculations, a P value 0.05 was con-
sidered as the level of signiﬁcance.
RESULTS— Baselinecharacteristicsof
all three groups included are given in
Table 1. IOP was comparable in all three
groups. In the diabetic group, A1C was








Sex (n) (male/female) 7/13 17/23 7/13
Age (years) 37  11 47  11* 38  12
MAP (mmHg) 82  89 0  11* 83  8
Cholesterol (mmol/l) 0.50  0.10 0.65  0.10* 0.45  0.05
A1C (%) 7.5  1.3* 5.6  0.4 5.2  0.3
IOP (mmHg) 13  21 4  21 4  3
Retinal artery diameter (m) 130  20* 118  16 117  14
Retinal vein diameter (m) 156  24 151  21 153  19
Data are means  SD, unless otherwise indicated.*Signiﬁcant differences (P  0.05, ANOVA).
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othergroups(ANOVA,P0.001)(Table
1). MAP and total cholesterol were in-
creased in group 2 (ANOVA, P  0.003).
Bloodglucoselevelsatthetimeofmeasure-
ment were 8.4  3.4 mmol/l in patients
withdiabetes.Averagebaselinevesseldiam-
eters were slightly increased in type 1 dia-
betes (ANOVA, P  0.018). A detailed
summaryofconcomitantmedicationcanbe
found in online appendix Table A1 (avail-
ableathttp://care.diabetesjournals.org/cgi/
content/full/dc08-2130/DC1). Subjects in
the healthy control group were medica-
tion free. Flicker stimulation did not af-
fect IOP or MAP in any of the groups.
Flicker-induced vasodilatation
In the healthy group, stimulation with
ﬂicker light induced a vasodilatation of
7.0  2.3% in retinal arteries (ANOVA,
time effect, P  0.001) (Fig. 1) and a di-
latation of 6.8  3.4% (P  0.001) in
retinal veins. In patients with type 1 dia-
betes, retinal arterial diameters increased
by 2.9  2.8% (P  0.001) and retinal
veinsby4.62.0%(P0.001).Patients
withsystemichypertensionand/orhyper-
cholesterolemia showed a vasodilatation
of 4.3  2.8% (P  0.001) in retinal ar-
teries and a vasodilatation of 6.0  2.4%
(P0.001)inretinalveins.Thus,ﬂicker-
induced dilatation was reduced in pa-
tients with type 1 diabetes and patients
withsystemichypertensionand/orhyper-
cholesterolemia compared with healthy
control subjects. This effect was signiﬁ-
cant at a level of P  0.001 for retinal
arteries and at a level of P  0.045 for
retinal veins (ANOVA, effect between
groups).Resultsbetweenthetwopatients
groups, however, were not signiﬁcantly
different.
FMD
FMD of the brachial artery was 4.3 
3.0% in the healthy group (ANOVA, time
effect, P  0.001) (Fig. 1). In both pa-
tients with type 1 diabetes and patients
withsystemichypertensionand/orhyper-
cholesterolemia, FMD was signiﬁcantly
attenuated to 2.6  1.7% in group 1
(ANOVA; time effect: P  0.001; effect
between groups:P  0.045) and to 2.4
2.4% in group 2 (time effect: P  0.001;
effectbetweengroups:P0.045).Again,
FMD of the brachial artery was not signif-
icantly different between the two patients
groups.
Correlation analysis
A correlation between FMD and ﬂicker-
induced vasodilatation in retinal arteries
(r  0.3, P  0.044) was found (Fig. 2).
No correlation, however, was observed
between FMD and ﬂicker response in ret-
inal veins (data not shown). Flicker-
induced vasodilatation was negatively
correlated with plasma cholesterol levels
(r  0.33, P  0.044) but not with age
(r0.33,P0.08)(Fig.3).Therewas
also no signiﬁcant correlation between
FMD and age (r  0.35, P  0.081) or
cholesterol (r  0.22, P  0.090) after
P value adjustment. Given that patients
with diabetes are known to have a re-
ducedﬂickerresponse,thetype1diabetic
group has been excluded in the latter
analyses.
CONCLUSIONS — Given that im-
paired endothelial function has been ob-
served to be an early feature in several
systemic and ocular vascular-related dis-
eases,muchattentionhasbeenpaidtothe
developmentofmethodstononinvasively
assess endothelial function in humans. As
one of the most widely used techniques,
the ultrasound-based FMD has been
shown to give a reliable estimate of endo-
thelium-dependent vasodilatation (10).
FMD is based on the capacity of blood
vesselstoself-regulatevasculartoneinre-
sponse to changes of shear stress caused
by changes in blood ﬂow. This regulation
is dependent on endothelium-derived
NO (14) and can therefore be used as a
marker for endothelial function.
Reduced FMD has been found in pa-
tients with mild systemic hypertension
(15), hypercholesterolemia (16), and dia-
betes (17), indicating for an impaired en-
dothelialfunctioninthesepatientgroups.
Additionally,ithasbeenshownthatFMD
can predict future cardiovascular events
(18). However, the technique of FMD is
hampered by the limited spatial resolu-
tion of the ultrasound systems currently
available. In addition, measurement of
FMD requires signiﬁcant training and in-
volves a subjective component when data
are evaluated.
Flicker-induced vasodilatation may
be another attractive noninvasive ap-
proach. It has been shown that ﬂicker re-
sponse is signiﬁcantly diminished in
Figure 1—Flicker-induced vasodilatation and FMD in the three different groups included. Group means  SD. *Signiﬁcant differences (P  0.05,
ANOVA).
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Even more importantly, a reduced re-
sponse has also been observed in patients
with systemic hypertension, indicating a
potential insight into vascular function in
general (7), because an increase of blood
pressure or IOP alone does not inﬂuence
theﬂickerresponse(19,20).Theseresults
support the hypothesis that the observed
changes reﬂect long-term alterations of
the vasculature. The hypothesis that
ﬂicker-induced vasodilatation may at
least partially reﬂect endothelial function
has also been encouraged by the observa-
tion that ﬂicker-induced vasodilatation is
mainly dependent on an intact NO syn-
thesis (9). Endothelial dysfunction due to
abnormalreleaseoractionofNOisawell-
recognized early feature of vascular dam-
age, as it has been reported previously in
vascular-related diseases like diabetes,
hypercholesterolemia, systemic hyper-
tension, and atherosclerosis (16,21,22).
Ourﬁndingsofgreaterbaselinevessel
diameters in patients with diabetes are in
goodaccordancewithearlierstudies(23).
However, given that our measures were
done only in one single artery and vein
and not in all visible vessels, our data do
not represent total cross-sectional retinal
vessel diameters.
We observed a negative correlation
between ﬂicker-induced vasodilatation
and blood cholesterol. This result is again
a hint that endothelial dysfunction is in-
volvedinreducedﬂicker-inducedvasodi-
latation,becausecholesterolandoxidized
LDL in particular are clearly associated
withendothelialcelldysfunction(24)and
reduced bioavailability of NO. Evidence
has been provided that reduction of se-
rum cholesterol increases FMD and may
therefore be beneﬁcial for endothelial
functions (22,24). Whether this also
holds true for ﬂicker-induced vasodilata-
tion has yet to be clariﬁed. Correlations
between FMD and age or plasma choles-
terol, as observed earlier (16), and be-
tween ﬂicker-induced vasodilatation and
age failed to reach level of signiﬁcance af-
ter adjustment for multiple testing. Our
study was, however, not designed for
these outcome analyses, and a larger sam-
ple size may be required to investigate
these issues. The present study provides
evidence that in patients with type 1 dia-
betesandinpatientswithsystemichyper-
tension and/or hypercholesterolemia,
both FMD and ﬂicker-induced vasodila-
tationarereducedcomparedwithhealthy
volunteers. However, our study failed to
show a strong correlation between FMD
and ﬂicker-induced vasodilatation.
What could be the reason for the dif-
feringresponsesbetweenthetwovascular
beds? First and most importantly, FMD
and ﬂicker-light–induced vasodilatation
differ in the method of stimulation.
Whereas the diameter increase in FMD is
caused directly by the augmented shear
stress in the endothelium and the con-
nected tissue, ﬂicker response is basically
the vascular answer to increased neural
activity in the retina. This may be of spe-
cial importance in patients with diabetes
or glaucoma, since it cannot be ruled out
that in these patients decreased neural ac-
tivity may partially account for the de-
creased ﬂicker response.
Second, it has to be noted that the
properties of the vascular beds investi-
gated differ signiﬁcantly. Whereas ﬂicker
stimulation investigates arteries in an or-
der of 150–250 m, FMD reﬂects endo-
thelial function in signiﬁcantly larger
vessels with different vessel wall proper-
ties. Thus, the weak correlation between
FMD and ﬂicker may indicate that the
stimulation answer in the conduit arteries
and in the smaller retinal arteries do not
carry the same information, although
both are diminished in patients with en-
dothelial dysfunction. This phenomenon
is also known from other experiments
showing that FMD and endothelium-
dependent vasodilatation assessed with
an invasive technique that mainly reﬂects
the endothelial function of resistance ar-
teries are both independently related to
the risk of coronary heart disease (25).
Flicker-induced vasodilatation may pro-
vide additional information to these tech-
niques because of the smaller size of
vessels assessed. This may particularly be
interesting in diseases primarily affecting
the microvasculature.
Flicker-induced vasodilatation offers a
varietyofsigniﬁcantadvantages.Ontheone
hand, it provides excellent reproducibility
andsensitivity(12).Ontheotherhand,itis
easily performed and quick, although pupil
dilatation is required with the fundus cam-
era used in the present experiments. Most
importantly, the system does not include a
subjectivecomponentonceanoptimalfun-
dus image is achieved.
As a limitation of the study, no infor-
mation is available about blood nitrate
concentration. Although none of the sub-
jects under study was under nitrate med-
ication, we cannot fully exclude that a
nitrate-rich diet may inﬂuence FMD or
ﬂicker-induced vasodilatation.
In summary, our data indicate that in
both patient groups with endothelial dys-
function as assessed with FMD, ﬂicker re-
sponses are diminished. The reason why
no major correlation was found between
FMD and ﬂicker-induced vasodilatation
needs to be the subject of further studies.
Furthermore, whether ﬂicker stimulation
may also serve as a predictor for risk of
Figure 2—Correlation analysis between FMD and ﬂicker response of retinal arteries (r  0.3,
P  0.044).
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FMD, has yet to be investigated in longi-
tudinal studies. The system is, however, a
candidate for assessing endothelial func-
tion in clinical routine because it induces
minimum discomfort to the subject, pro-
vides good reproducibility and sensitiv-
ity, and does not include a subjective
component.
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